NK
Navneetam Kunal
About Navneetam Kunal
Data last updated:
Navneetam Kunal is a Director at Remedium Powertech Private Limited (since 2023) and Director at Vaniba Pharmaceutical Private Limited (since 2026). The companies operate in Construction. The largest current company by reported revenue is Remedium Powertech Private Limited at ₹28,000 (FY 2020).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Remedium Powertech Private Limited U45100BR2018PTC038968 | Director | 06 May 2023 | 2018 | ₹28,000 (FY 2020) | Active |
| Vaniba Pharmaceutical Private Limited U47721DC2026PTC472245 | Director | 15 Jun 2026 | 2026 | Active |
Board colleagues of Navneetam Kunal
| Name | DIN | Company | Designation |
|---|---|---|---|
| Praveen Kumar | 10125437 | Remedium Powertech Private Limited | Director |
| Anita Kumari | 11769850 | Vaniba Pharmaceutical Private Limited | Director |
| Vikash Kumar | 11769849 | Vaniba Pharmaceutical Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Navneetam Kunal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Navneetam Kunal
Navneetam Kunal currently holds 2 directorships: Remedium Powertech Private Limited (Director, since 06 May 2023, revenue ₹28,000 (FY 2020)); Vaniba Pharmaceutical Private Limited (Director, since 15 Jun 2026).
Navneetam Kunal was first appointed on 06 May 2023 as Director at Remedium Powertech Private Limited. The most recent appointment on record is 15 Jun 2026 at Vaniba Pharmaceutical Private Limited.
The current boards of Navneetam Kunal's companies include Praveen Kumar (Remedium Powertech Private Limited), Anita Kumari (Vaniba Pharmaceutical Private Limited), Vikash Kumar (Vaniba Pharmaceutical Private Limited).